OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hematology & Oncology is 89. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	492
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	486
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	484
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast	471
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	465
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	407
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	392
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	363
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	356
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	338
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial	330
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation	305
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	303
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients	290
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	280
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	277
Cancer vaccines: current status and future directions	276
Landscape of biallelic DNMT3A mutant myeloid neoplasms	261
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	256
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response	248
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	233
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma	227
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	221
Personalized nanovaccines for treating solid cancer metastases	219
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	214

NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	213
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	193
Targeting CD47 for cancer immunotherapy	187
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	184
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	180
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	177
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	164
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	163
Ferroptosis: principles and significance in health and disease	163
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	161
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	160
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	159
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	159
Recent advances in therapeutic strategies for non-small cell lung cancer	155
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	154
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	152
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	149
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	146
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	139
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	139
Small RNA modifications: regulatory molecules and potential applications	137
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers	136
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	134
3D chromatin architecture and transcription regulation in cancer	132
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	131
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	129
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	127
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1	125
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	124
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	123
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	120
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	119
Recent advances in targeted strategies for triple-negative breast cancer	118
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	117
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	117
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	117
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	115
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	111
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study	110
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	109
A single-cell and spatially resolved atlas of human osteosarcomas	109
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	109
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	108
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure	107
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	107
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth	107
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	106
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	105
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	105
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	104

LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	104
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	100
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	99
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	99
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	98
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	98
HLA alleles associated with asparaginase hypersensitivity in Chinese children	96
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	96
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	93
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	93
Metabolic landscapes in sarcomas	92
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	92
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	90
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	90